Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
Trial details
- Registry ID
- NCT04784091
- Drugs studied
- TP-03, TP-03 Vehicle
TrialRedline tracks 9 clinical trials sponsored by Tarsus Pharmaceuticals, Inc.: 1 Phase 3, 1 Phase 2 / 3, 7 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex BlepharitisNCT04784091 | TP-03, TP-03 Vehicle | Completed | 2022-05-09Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Safety and Efficacy of TP-03 for the Treatment of Demodex BlepharitisNCT04475432 | TP-03 Vehicle, TP-03, 0.25% | Completed | 2021-05-04Actual |
Names as written in the registry records.
NCT07562087 · Tarsus Pharmaceuticals, Inc.
Before: Estimated. After: Actual.
Before: 700 participants (planned). After: 722 participants (actual).
Before: Recruiting. After: Active not recruiting.